Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1-34 in the Treatment of Osteoporosis in Men and Postmenopausal Women

Authors

  • Armen H. Tashjian JR. M.D.,

    Corresponding author
    1. Department of Cancer Cell Biology, Harvard School of Public Health, Boston, Massachusetts, USA
    2. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA
    • Department of Cancer Cell Biology, Harvard School of Public Health, Building 1, Room 1202, 665 Huntington Avenue, Boston, MA 02115, USA
    Search for more papers by this author
    • Dr. Tashjian serves as a consultant to Eli Lilly and Company. Dr. Chabner has financial interests in the form of equity interests in Eli Lilly, Immunex, Johnson and Johnson, Gilead and Pfizer. Dr. Chabner serves as a board member for Kosan Bioscience and Vion. In addition, he serves as a consultant for Eli Lilly and PharmaMar.

  • Bruce A. Chabner

    1. Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA
    2. Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Search for more papers by this author

Ancillary